Targeting nuclear receptors for NASH/MASH:From bench to bedside

作     者：Rohit A.Sinha Rohit A.Sinha

作者机构：Department of EndocrinologySanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia 

出 版 物：《Liver Research》 (肝脏研究（英文）)

年 卷 期：2024年第8卷第1期

页      面：34-45页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the SERB(CRC/2022/002149) Wellcome Trust/DBT India Alliance Fellowship[IA/I/16/2/502691] 

主　　题：Nuclear receptor(NR) Metabolic dysfunction-associated steatohepatitis(MASH) Metabolic dysfunction-associated steatotic liver disease(MASLD) Transcription factor Liver Drug 

摘      要：The onset of metabolic dysfunction-associated steatohepatitis(MASH)or non-alcoholic steatohepatitis(NASH)represents a tipping point leading to liver injury and subsequent hepatic complications in the natural progression of what is now termed metabolic dysfunction-associated steatotic liver diseases(MASLD),formerly known as non-alcoholic fatty liver disease(NAFLD).With no pharmacological treat-ment currently available for MASH/NASH,the race is on to develop drugs targeting multiple facets of hepatic metabolism,inflammation,and pro-fibrotic events,which are major drivers of *** receptors(NRs)regulate genomic transcription upon binding to lipophilic ligands and govern multiple aspects of liver metabolism and *** of NRs may include hormones,lipids,bile acids,and synthetic ligands,which upon binding to NRs regulate the transcriptional activities of target *** ligands are presently the most promising drug candidates expected to receive approval from the United States Food and Drug Administration as a pharmacological treatment for *** review aims to cover the current understanding of NRs,including nuclear hormone receptors,non-steroid hormone receptors,circadian NRs,and orphan NRs,which are currently undergoing clinical trials for MASH treatment,along with NRs that have shown promising results in preclinical studies.